MRI-Guided Laser Induced Thermal Therapy
Status: | Completed |
---|---|
Conditions: | Brain Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 11/18/2012 |
Start Date: | August 2011 |
End Date: | August 2014 |
Contact: | Joan Glenn |
Email: | glenn@umdnj.edu |
MRI-Guided Laser-Induced Thermal Therapy for Cytoreduction of Inoperable Grade III/IV GLiomas Prior to Chemotherapy and Radiation
Does MR-guided laser interstitial thermal therapy (MRgLITT) prior to chemotherapy and/or
radiation give patients a beneficial increase in overall survival? Laser induced thermal
therapy (LITT) is a minimally invasive procedure for destroying tissue through generation of
heat.
Laser induced thermal therapy (LITT) is a procedure for destroying tissue through generation
of heat. When used in conjunction with fiberoptic applicators, it offers an excellent means
of minimally invasive surgery. As opposed to other thermal techniques like radio-frequency
(RF) ablation, or cryo-ablation, LITT may be significantly faster and may exhibit sharper
boundary of the thermal ablation zone. More importantly, LITT is highly compatible with MR
imaging and when coupled with MR thermal imaging (MRTI) guidance, precise monitoring of the
thermal ablation zone in order to avoid eloquent or critical structures is possible.
In this study, we propose to evaluate MR-thermal image guided laser interstitial therapy for
the treatment of inoperable brain tumors as upfront therapy prior to initiation of
chemotherapy and radiation. MR-thermal imaging (MRTI) will be used to provide information
on thermal dose delivered to the target and be used to control laser delivery to prevent
damage to critical structures.
Inclusion Criteria:
- Subjects that have/will undergo MRgLITT for inoperable brain tumor.
- Tumor size < 3cm in transverse diameter for each planned applicator placement.
- Tumor size < 4 cm in largest dimension.
- Lesion(s) are clearly defined on pre-therapy contrast enhanced MRI scans as
determined by the treating surgeon.
- Karnofsky Performance Scale score > 70.
- ECOG performance status of 2 or better.
- Biopsy proven histologic diagnosis of malignant glioma.
Exclusion Criteria:
- Patients with co-existing medical conditions with life expectancy < 1 year.
- Patients having received pre-ablation chemotherapy and/or radiation to lesion.
We found this trial at
1
site
Click here to add this to my saved trials